Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15237105rdf:typepubmed:Citationlld:pubmed
pubmed-article:15237105lifeskim:mentionsumls-concept:C0021368lld:lifeskim
pubmed-article:15237105lifeskim:mentionsumls-concept:C0384648lld:lifeskim
pubmed-article:15237105lifeskim:mentionsumls-concept:C1539477lld:lifeskim
pubmed-article:15237105lifeskim:mentionsumls-concept:C1314939lld:lifeskim
pubmed-article:15237105pubmed:issue8lld:pubmed
pubmed-article:15237105pubmed:dateCreated2004-7-19lld:pubmed
pubmed-article:15237105pubmed:abstractTextFas ligand (FasL) has been well characterized as a death factor. However, recent studies revealed that ectopic expression of FasL induces inflammation associated with massive neutrophil infiltration. We previously demonstrated that the neutrophil infiltration-inducing activity of FasL is partly dependent on, but partly independent of, IL-1beta. Here we investigated the cytokine profile of peritoneal lavage fluid obtained from mice that received i.p. injections of FFL, a FasL-expressing tumor cell line. We found that FFL injection caused a marked increase of not only IL-1beta but also IL-6, IL-17, IL-18, KC/chemokine CXC ligand 1 and macrophage inflammatory protein (MIP)-2, but not of IL-1alpha, IFN-gamma, TGF-beta or TNF-alpha. The FFL-induced cytokine production was not observed in Fas-deficient lpr mice. Among cells transfected to express individually IL-1beta, IL-6, IL-17, or IL-18, only those expressing IL-1beta and IL-17 induced neutrophil infiltration. In these analyses, as little as 20 pg of peritoneal IL-17 induced neutrophil infiltration. The peritoneal IL-17 levels after FFL-injection were greatly diminished in IL-1-deficient mice. However, the IL-17 level was still above the threshold for neutrophil infiltration. Consistent with this, co-administration of the anti-IL-17 antibody with FFL diminished the peritoneal KC levels and neutrophil infiltration in IL-1-deficient mice. In addition, the expression of IL-17 by the tumor cells inhibited tumor growth in wild-type and nude mice. These results indicate that FasL is an upstream inflammatory factor that induces a variety of other inflammatory cytokines in vivo, and suggest that IL-17 is involved in FasL-induced inflammation in the absence of IL-1beta.lld:pubmed
pubmed-article:15237105pubmed:languageenglld:pubmed
pubmed-article:15237105pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15237105pubmed:citationSubsetIMlld:pubmed
pubmed-article:15237105pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15237105pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15237105pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15237105pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15237105pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15237105pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15237105pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15237105pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15237105pubmed:statusMEDLINElld:pubmed
pubmed-article:15237105pubmed:monthAuglld:pubmed
pubmed-article:15237105pubmed:issn0953-8178lld:pubmed
pubmed-article:15237105pubmed:authorpubmed-author:IwakuraYoichi...lld:pubmed
pubmed-article:15237105pubmed:authorpubmed-author:SudaTakashiTlld:pubmed
pubmed-article:15237105pubmed:authorpubmed-author:AsanoMasahide...lld:pubmed
pubmed-article:15237105pubmed:authorpubmed-author:MatsuzakiGoro...lld:pubmed
pubmed-article:15237105pubmed:authorpubmed-author:UmemuraMasayu...lld:pubmed
pubmed-article:15237105pubmed:authorpubmed-author:FukuiMasayuki...lld:pubmed
pubmed-article:15237105pubmed:authorpubmed-author:ImamuraRyuRlld:pubmed
pubmed-article:15237105pubmed:authorpubmed-author:KawabeTakayaTlld:pubmed
pubmed-article:15237105pubmed:authorpubmed-author:ShudoKoyoKlld:pubmed
pubmed-article:15237105pubmed:authorpubmed-author:KidoyaHiroyas...lld:pubmed
pubmed-article:15237105pubmed:issnTypePrintlld:pubmed
pubmed-article:15237105pubmed:volume16lld:pubmed
pubmed-article:15237105pubmed:ownerNLMlld:pubmed
pubmed-article:15237105pubmed:authorsCompleteYlld:pubmed
pubmed-article:15237105pubmed:pagination1099-108lld:pubmed
pubmed-article:15237105pubmed:dateRevised2007-1-6lld:pubmed
pubmed-article:15237105pubmed:meshHeadingpubmed-meshheading:15237105...lld:pubmed
pubmed-article:15237105pubmed:meshHeadingpubmed-meshheading:15237105...lld:pubmed
pubmed-article:15237105pubmed:meshHeadingpubmed-meshheading:15237105...lld:pubmed
pubmed-article:15237105pubmed:meshHeadingpubmed-meshheading:15237105...lld:pubmed
pubmed-article:15237105pubmed:meshHeadingpubmed-meshheading:15237105...lld:pubmed
pubmed-article:15237105pubmed:meshHeadingpubmed-meshheading:15237105...lld:pubmed
pubmed-article:15237105pubmed:meshHeadingpubmed-meshheading:15237105...lld:pubmed
pubmed-article:15237105pubmed:meshHeadingpubmed-meshheading:15237105...lld:pubmed
pubmed-article:15237105pubmed:meshHeadingpubmed-meshheading:15237105...lld:pubmed
pubmed-article:15237105pubmed:meshHeadingpubmed-meshheading:15237105...lld:pubmed
pubmed-article:15237105pubmed:meshHeadingpubmed-meshheading:15237105...lld:pubmed
pubmed-article:15237105pubmed:meshHeadingpubmed-meshheading:15237105...lld:pubmed
pubmed-article:15237105pubmed:meshHeadingpubmed-meshheading:15237105...lld:pubmed
pubmed-article:15237105pubmed:meshHeadingpubmed-meshheading:15237105...lld:pubmed
pubmed-article:15237105pubmed:year2004lld:pubmed
pubmed-article:15237105pubmed:articleTitleInvolvement of IL-17 in Fas ligand-induced inflammation.lld:pubmed
pubmed-article:15237105pubmed:affiliationCenter for the Development of Molecular Target Drugs, Cancer Research Institute, Graduate School of Medicine Science, Kanazawa University, Takaramachi, Japan.lld:pubmed
pubmed-article:15237105pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15237105pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:14103entrezgene:pubmedpubmed-article:15237105lld:entrezgene
entrez-gene:16171entrezgene:pubmedpubmed-article:15237105lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15237105lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15237105lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15237105lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15237105lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15237105lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15237105lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15237105lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15237105lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15237105lld:pubmed